Journal
RESPIROLOGY
Volume 21, Issue 3, Pages 519-525Publisher
WILEY-BLACKWELL
DOI: 10.1111/resp.12696
Keywords
chemotherapy response; circulating tumour cell; non-small cell lung cancer; overall survival; progression-free survival
Categories
Funding
- Peking Union Medical College Hospital
Ask authors/readers for more resources
Background and objectiveThis study investigated whether circulating tumour cells (CTC) are detectable in patients with non-small cell lung cancer (NSCLC) and whether CTC count could provide prognostic information or serve as an indicator of patient response to chemotherapy. MethodsWe enrolled 46 patients with newly diagnosed or recurrent NSCLC. CTC were measured at baseline in all patients and in 23 patients, CTC were also measured before every chemotherapy cycle. The relationship between CTC count and tumour size was analysed. ResultsCTC were present in 40 patients (87%); among them, 29 (63%) had a CTC count of 3 cells/3.2mL, 17 (37%) had a CTC count of 5 cells/3.2mL and 7 (15.2%) had a CTC count of 8 cells/3.2mL. The median progression-free survival (PFS) and overall survival (OS) were 7.3 months and 16 months, respectively. A CTC count of more than eight prior to chemotherapy was a strong predictor of reduced PFS (P=0.018) and OS (P=0.026). A multivariate analysis indicated that baseline CTC count was an independent negative prognostic factor for survival. However, no correlation was observed between CTC count and tumour size after two chemotherapy cycles, its relationship with chemotherapy response still needs to be defined. ConclusionBaseline CTC count is an independent negative prognostic factor for NSCLC; The relationship of CTC and survival after chemotherapy still needs to be defined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available